ReutersCOVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on April 16.
The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.
A third shot of Sinopharm’s Covid-19 vaccine leads to a rebound in antibody levels that drop months after a second dose, a small-scale Chinese study showed.
Sinopharm’s Covid-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.
Two Covid-19 vaccines from China’s Sinopharm showed more than 70 percent efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public.
The World Health Organization (WHO) approved for emergency use a Covid-19 vaccine from China’s state-owned drugmaker Sinopharm on May 7, bolstering Beijing’s push for a bigger role in inoculating the world.
The World Health Organization expects to release its assessments for emergency use listing of the two main Chinese vaccines for Covid-19 as well as the Moderna shot by the end of next week, WHO Assistant Director-General Mariangela Simao said on April 30.
Leaked documents from provincial and municipal governments in China reveal a slew of previously unreported severe adverse events related to Covid-19 vaccines made and administered in China.
Technical experts at the World Health Organization (WHO) will review on April 26 Chinese drugmaker Sinopharm’s Covid-19 vaccine for possible emergency use listing, to be followed by the Sinovac jab on May 3, the agency said on April 22.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
